blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2815763

EP2815763 - THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.04.2019
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  11.05.2018
FormerGrant of patent is intended
Status updated on  03.01.2018
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Josai University Corporation
3-26 Kioi-cho Chiyoda-ku
Tokyo 104-0092 / JP
[2014/52]
Inventor(s)01 / SATO, Shuji
c/o Kazusa Institute for Drug Discovery
2-1-6, Kazusa-Kamatari
Kisarazu-shi Chiba-ken 292-0818 / JP
02 / GOTO, Takeshi
c/o Kazusa Institute for Drug Discovery
2-1-6, Kazusa-Kamatari
Kisarazu-shi Chiba-ken 292-0818 / JP
03 / OHMORI, Naoya
c/o Kazusa Institute for Drug Discovery
2-1-6, Kazusa-Kamatari
Kisarazu-shi Chiba-ken 292-0818 / JP
04 / CHIANG, Kueichen
c/o Kazusa Institute for Drug Discovery
2-1-6, Kazusa-Kamatari
Kisarazu-shi Chiba-ken 292-0818 / JP
05 / SHIMADA, Yayoi
c/o Kazusa Institute for Drug Discovery
2-1-6, Kazusa-Kamatari
Kisarazu-shi Chiba-ken 292-0818 / JP
06 / INOMATA, Masafumi
c/o Department of Medicine
National University Corporation
Oita University
1-1 Idaigaoka, Hasamamachi
Yufu-shi Oita 879-5593 / JP
07 / KUSANO, Toru
c/o Department of Medicine
National University Corporation
Oita University
1-1 Idaigaoka, Hasamamachi
Yufu-shi Oita 879-5593 / JP
08 / HIRATSUKA, Takahiro
c/o Department of Medicine
National University Corporation
Oita University
1-1 Idaigaoka, Hasamamachi
Yufu-shi Oita 879-5593 / JP
09 / NOGUCHI, Takayuki
c/o Department of Medicine
National University Corporation
Oita University
1-1 Idaigaoka, Hasamamachi
Yufu-shi Oita 879-5593 / JP
10 / HAGIWARA, Satoshi
c/o Department of Medicine
National University Corporation
Oita University
1-1 Idaigaoka, Hasamamachi
Yufu-shi Oita 879-5593 / JP
 [2014/52]
Representative(s)Prüfer & Partner mbB Patentanwälte · Rechtsanwälte
Sohnckestraße 12
81479 München / DE
[2018/24]
Former [2014/52]Prüfer & Partner GbR European Patent Attorneys
Sohnckestrasse 12
81479 München / DE
Application number, filing date13751092.122.02.2013
[2018/24]
WO2013JP54551
Priority number, dateJP2012003596522.02.2012         Original published format: JP 2012035965
[2014/52]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013125687
Date:29.08.2013
Language:JA
[2013/35]
Type: A1 Application with search report 
No.:EP2815763
Date:24.12.2014
Language:EN
[2014/52]
Type: B1 Patent specification 
No.:EP2815763
Date:13.06.2018
Language:EN
[2018/24]
Search report(s)International search report - published on:JP29.08.2013
(Supplementary) European search report - dispatched on:EP22.06.2015
ClassificationIPC:A61K39/395, A61P13/12, A61P29/00, A61P31/04, C07K7/06, C07K16/44, C12N5/10, C12N15/09, C07K7/08, C07K16/18, A61K39/00
[2015/30]
CPC:
C07K16/44 (EP,US); C07K16/18 (US); A61P13/12 (EP);
A61P29/00 (EP); A61P31/04 (EP); C07K14/47 (EP,US);
A61K2039/505 (EP,US); C07K2317/14 (US); C07K2317/21 (US);
C07K2317/24 (US); C07K2317/34 (US); C07K2317/55 (US);
C07K2317/56 (US); C07K2317/565 (US); C07K2317/622 (US);
C07K2317/76 (US) (-)
Former IPC [2014/52]A61K39/395, A61P13/12, A61P29/00, A61P31/04, C07K7/06, C07K16/44, C12N5/10, C12N15/09
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/52]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:HEILMITTEL FÜR ENTZÜNDUNGSERKRANKUNGEN[2014/52]
English:THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE[2014/52]
French:AGENT THÉRAPEUTIQUE POUR MALADIE INFLAMMATOIRE[2014/52]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase18.09.2014Translation filed 
18.09.2014National basic fee paid 
18.09.2014Search fee paid 
18.09.2014Designation fee(s) paid 
18.09.2014Examination fee paid 
Examination procedure31.07.2013Request for preliminary examination filed
International Preliminary Examining Authority: JP
18.09.2014Examination requested  [2014/52]
13.01.2016Amendment by applicant (claims and/or description)
14.06.2016Despatch of a communication from the examining division (Time limit: M04)
11.10.2016Reply to a communication from the examining division
09.11.2017Cancellation of oral proceeding that was planned for 10.11.2017
10.11.2017Date of oral proceedings (cancelled)
04.01.2018Communication of intention to grant the patent
03.05.2018Fee for grant paid
03.05.2018Fee for publishing/printing paid
03.05.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.06.2016
Opposition(s)14.03.2019No opposition filed within time limit [2019/21]
Fees paidRenewal fee
25.02.2015Renewal fee patent year 03
26.02.2016Renewal fee patent year 04
27.02.2017Renewal fee patent year 05
27.02.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.02.2013
AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
MK13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
PT15.10.2018
IE22.02.2019
LU22.02.2019
MT22.02.2019
BE28.02.2019
CH28.02.2019
LI28.02.2019
[2022/31]
Former [2021/32]HU22.02.2013
AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
PT15.10.2018
IE22.02.2019
LU22.02.2019
MT22.02.2019
BE28.02.2019
CH28.02.2019
LI28.02.2019
Former [2020/29]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
PT15.10.2018
IE22.02.2019
LU22.02.2019
MT22.02.2019
BE28.02.2019
CH28.02.2019
LI28.02.2019
Former [2020/16]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
IE22.02.2019
LU22.02.2019
BE28.02.2019
CH28.02.2019
LI28.02.2019
Former [2020/12]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
IE22.02.2019
LU22.02.2019
BE28.02.2019
CH28.02.2019
LI28.02.2019
Former [2020/09]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
IE22.02.2019
LU22.02.2019
CH28.02.2019
LI28.02.2019
Former [2020/04]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
LU22.02.2019
CH28.02.2019
LI28.02.2019
Former [2019/51]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
LU22.02.2019
Former [2019/47]AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
LU22.02.2019
Former [2019/45]AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/26]AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/11]AT13.06.2018
CY13.06.2018
CZ13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/10]AT13.06.2018
CY13.06.2018
CZ13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SK13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/09]CY13.06.2018
EE13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/08]CY13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/03]CY13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
Former [2018/52]CY13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
Former [2018/51]CY13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
Former [2018/50]CY13.06.2018
ES13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
Former [2018/49]CY13.06.2018
ES13.06.2018
FI13.06.2018
LT13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
Former [2018/47]ES13.06.2018
FI13.06.2018
LT13.06.2018
NO13.09.2018
Documents cited:Search[I]US2009117099  (ESMON CHARLES T [US], et al) [I] 1-15 * abstract, p. 1 [0007] - [0012] in particular p. 2 left-hand column lines 3-6, p. 3 [0035] and Fig. 15A-C, p. 8 [0111]-[0121], p. 11 [0144] - p. 13 [0166], p. 14 [0190] - p. 16 [0202] and example 4 [0233] and example 5, claims 11-13 *;
 [XP]WO2012023614  (JOSAI UNIVERSITY CORP [JP], et al) [XP] 1-15 * abstract, [0014] - [0018], [0020] - [0030], examples 1-6 and claims 1-22 *;
 [I]  - JUN XU ET AL, "Extracellular histones are major mediators of death in sepsis", NATURE MEDICINE, (20091101), vol. 15, no. 11, doi:10.1038/nm.2053, ISSN 1078-8956, pages 1318 - 1321, XP055082137 [I] 1-15 * abstract, p. 1320 right-hand column line 3 - p. 1321 left-hand column last paragraph, Fig. 3 and 4 *

DOI:   http://dx.doi.org/10.1038/nm.2053
 [A]  - CATHERINE CHAPUT ET AL, "Sepsis: the dark side of histones", NATURE MEDICINE, (20091101), vol. 15, no. 11, doi:10.1038/nm1109-1245, ISSN 1078-8956, pages 1245 - 1246, XP055194652 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/nm1109-1245
 [A]  - HAI HUANG ET AL, "Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice", HEPATOLOGY, (20110902), vol. 54, no. 3, doi:10.1002/hep.24501, ISSN 0270-9139, pages 999 - 1008, XP055194650 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1002/hep.24501
 [A]  - K.-C. CHIANG ET AL, "A Novel Peptide Mimotope Identified As a Potential Immunosuppressive Vaccine for Organ Transplantation", THE JOURNAL OF IMMUNOLOGY, (20090401), vol. 182, no. 7, doi:10.4049/jimmunol.0800641, ISSN 0022-1767, pages 4282 - 4288, XP055082127 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.4049/jimmunol.0800641
 [A]  - T. A. FUCHS ET AL, "Histones induce rapid and profound thrombocytopenia in mice", BLOOD, (20110623), vol. 118, no. 13, doi:10.1182/blood-2011-01-332676, ISSN 0006-4971, pages 3708 - 3714, XP055194648 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood-2011-01-332676
 [T]  - TORU KUSANO ET AL, "A Novel Anti-Histone H1 Monoclonal Antibody, SSV Monoclonal Antibody, Improves Lung Injury and Survival in a Mouse Model of Lipopolysaccharide-Induced Sepsis-Like Syndrome", BIOMED RESEARCH INTERNATIONAL, (20150101), vol. 61, no. 4, doi:10.1002/eji.1830260726, ISSN 2314-6133, pages 1496 - 10, XP055194646 [T] * the whole document *

DOI:   http://dx.doi.org/10.1155/2015/491649
International search[X]WO2006025580  (AMATERASPHARMA INC [JP], et al);
 [Y]JP2011503012  (OKLAHOMA MEDICAL RESEARCH FOUNDATION);
 [XP]WO2012023614  (JOSAI UNIVERSITY CORP [JP], et al);
 [X]  - KUEI-CHEN CHIANG, ET AL., "A Novel Peptide Mimotope Identified As a Potential Immunosuppressive Vaccine for Organ Transplantation", J.IMMUNOL., (20090401), vol. 182, pages 4282 - 4288, XP055082127

DOI:   http://dx.doi.org/10.4049/jimmunol.0800641
 [A]  - JUN XU, ET AL., "Extracellular histones are major mediators of death in sepsis", NATURE MEDICINE, (2009), vol. 15, no. 11, pages 1318 - 1322, XP055082137

DOI:   http://dx.doi.org/10.1038/nm.2053
 [A]  - JUN XU, ET AL., "Extracellular Histones Are Mediators of Death through TLR2 and TLR4 in Mouse Fatal Liver Injury", J.IMMUNOL., (2011), vol. 187, pages 2626 - 2631, XP055082161

DOI:   http://dx.doi.org/10.4049/jimmunol.1003930
ExaminationEP1820855
 EP2196212
by applicantWO2006025580
    - CRIT. CARE MED., (1992), vol. 20, pages 864 - 874
    - CHEST, (1992), vol. 101, pages 1644 - 1655
    - NATH. J. MED., (1999), vol. 55, pages 132 - 141
    - LANCET, (1998), vol. 351, pages 929 - 933
    - JAMA, (1994), vol. 271, pages 1836 - 1843
    - MORRISON, S.L.; OI, V. T., immunoglobulin genes, ACADEMIC PRESS, (1989), pages 260 - 274
    - ROGUSKA, M. L., "Humanization of murine monoclonal antibodies through variable domain resurfacing", PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 969 - 973
    - TOMIZUKA, K., "Functional expression and germline transmission of a human chromosome fragment in chimaeric mice", NATURE GENET., (1997), vol. 16, pages 133 - 143
    - WINTER, G., "Making antibodies by phage display technology", ANN. REV. IMMUNOL., (1994), vol. 12, pages 433 - 455
    - GRIFFITHS, A. D., "Isolation of high affinity human antibodies directly from large synthetic repertoires", EMBO. J., (1994), vol. 13, pages 3245 - 3260
    - J. IMMUNOL., (1978), vol. 123, page 1548
    - CURRENT TOPICS IN MICRO-BIOLOGY AND IMMUNOLOGY, (1978), vol. 81, pages 1 - 7
    - EUR. J. IMMUNOL., (1976), vol. 6, pages 511 - 519
    - CELL, (1976), vol. 8, pages 405 - 415
    - NATURE, (1978), vol. 276, pages 269 - 270
    - J. IMMUNOL. METH., (1980), vol. 35, pages 1 - 21
    - J. EXP. MED., (1978), vol. 148, pages 313 - 323
    - NATURE, (1979), vol. 277, pages 131 - 133
    - MILSTEIN, METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46
    - HASEGAWA ET AL., SURG RES., (20120501), vol. 174, no. 1, pages 136 - 41
    - MURAKAMI ET AL., SHOCK, (2002), vol. 18, page 236
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.